EffRx created Binosto® by taking this product from start to finish, including benefit assessment, formulation development, clinical development, FDA approval through a 505(b)(2) route, licensing to and launch via commercial partners.

The approval and commercial launch of Binosto® provides EffRx with an important proof-of-concept and highlights a number of potential benefits of EffRx‘ technology.

Bronchitol® is our lead pipeline product for Switzerland. It is intended for people living with cystic fibrosis, is dry powder mannitol which is inhaled twice daily using a small handheld device.

EX404 targets PolyCystic Ovarian Syndrome (PCOS) in adolescents and adults. EffRx received an orphan drug designation (ODD) from FDA in 2015 for the adolescent PCOS.